|
|
|
|
STUDIES AVAILABLE OF IMPOTENCE
Sources :- http://www.pubmedcentral.nih.gov
1. Int J Impot Res. 2011 Aug 4. doi: 10.1038/ijir.2011.34. [Epub ahead of print]
Efficacy and safety of combination therapy with mirodenafil and α(1)-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study.
Lee JY, Cho SY, Oh CY, Ha US, Lee SH, Park SY, Moon HS, Lee SW.
Department of Urology, Hanyang University College of Medicine, Seoul, Korea.
This study was conducted to determine whether mirodenafil 100 mg, when administered on demand to patients with benign prostatic hyperplasia (BPH) who
are receiving α(1)-blocker therapy, is safe with regard to the cardiovascular system and whether it improves lower urinary tract symptoms (LUTS) and sexual
function. The study involved 121 LUTS/BPH patients who had been treated for at least 3 months with α(1)-blockers before being administered with mirodenafil
100 mg on demand. Before the start of mirodenafil administration, the blood pressure, heart rate, international prostate symptom score (IPSS)/quality of life
(QoL), peak urine flow rate (Qmax), post-voiding residual urine volume (PVR), and international index of erectile function-5 (IIEF-5) of each patient were
measured. At 4 and 8 weeks after commencing mirodenafil administration, the blood pressure and heart rate were measured again, any adverse effects of mirodenafil were assessed, and sexual function and voiding symptoms were re-evaluated. Of the 121 patients, 73 (60.3%) completed the 8-week clinical trial. Significant changes in blood pressure and heart rate were not observed during the study. Significant improvements in the IIEF-5 and the IPSS/QoL, but not the Qmax or PVR, were observed. The results of this study suggest that the administration of mirodenafil 100 mg on demand may induce few hypotensive interactions and may be acceptably effective with regard to improving LUTS and sexual function.International Journal of Impotence Research advance online publication,
PMID: 21814227 [PubMed - as supplied by publisher]
2. Int J Impot Res. 2011 Aug 4. doi: 10.1038/ijir.2011.37. [Epub ahead of print]
Sexual function in male patients with ankylosing spondylitis.
Ozkorumak E, Karkucak M, Civil F, Tiryaki A, Ozden G.
Karadeniz Technical University Faculty of Medicine, Department of Psychiatry,Trabzon, Turkey.
Sexuality is an important part of healthy life. Patients with ankylosingspondylitis (AS) may be vulnerable to sexual problems because of disease activity
and comorbid emotional problems. However, sexuality is a scarcely studied subject in AS. The aim of this study is to compare patients with AS with healthy control. A total of 43 male patients, who referred to the Department of Physical Medicine and Rehabilitation Clinics of the Karadeniz Technical University Farabi Hospital between May 2010 and July 2010, and were diagnosed as AS according to modified New York criteria, were included in the study. Control group consisted of healthy 43 age- and sex-matched male individuals with normal inflammatory levels. The AS patients were compared in means of sociodemographic variables and sexual function with Glombok-Rust Sexual Satisfaction Scale (GRSSS) and clinical interview. Beck
Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) were used to determine anxiety and depression levels, respectively. The disease activity and
functional conditions were evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Metrology Index (BASMI) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDI). A total of 43 patients with AS and 43 healthy heterosexual male were included in the study. The total GRSSS score was significantly higher in patients with AS, whereas they also had significantly higher sexual complaint than healthy control. The diagnosis of sexual dysfunction according to DSM-IV was significantly higher in the patients with AS as well as depression and anxiety. In study group, GRSSS total score was modestly correlated with disease activity. The psychological status had close relation with sexual functions in AS. Overall assessment is required for complete evaluation in patients with AS.International Journal of Impotence Research advance online publication,
PMID: 21814226 [PubMed - as supplied by publisher]
3. Forensic Sci Int. 2011 Aug 1. [Epub ahead of print]
Capsule shells adulterated with tadalafil.
Venhuis BJ, Tan J, Vredenbregt MJ, Ge X, Low MY, de Kaste D.
RIVM - National Institute for Public Health and the Environment, P.O. Box 1,NL-3720 BA Bilthoven, The Netherlands.
Following a health complaint a food supplement was brought in for analysis on the suspicion of being adulterated with a synthetic drug substance. When the capsule content did not show evidence of adulteration, the capsule shell was investigated. Using HPLC-DAD and HPLC-MS the capsule shell was found to contain 2.85mg of the erectile dysfunction drug tadalafil. Using microscopy and RAMAN spectroscopy the presence of tadalafil was shown throughout the gelatine matrix as particles and dissolved into the matrix. The adulteration is probably carried out by adding tadalafil powder to a gelatine jelly in the manufacturing of the capsules shells. Because this technique may also be used for other drug substances, capsules shells should be considered a vehicle for hiding drug substances in general.
PMID: 21813256 [PubMed - as supplied by publisher]
4. Urologe A. 2011 Aug;50(8):977-84.
[Testosterone substitution therapy in prostate cancer].[Article in German]
Kaminsky A, Sperling H.
Klinik für Urologie, Kliniken Maria Hilf GmbH, Viersener Str. 450, 41063, Mönchengladbach, Deutschland, angelika.kaminsky@mariahilf.de.
After the fourth decade of life the total testosterone level in men decreases continually. If clinical symptoms, such as decreased libido or erectile
dysfunction are combined with a decreased serum testosterone level this is known as late onset hypogonadism (LOH) or partial androgen deficiency in the aging male (PADAM). In such cases testosterone substitution therapy is indicated. One important question is how to treat patients suffering from LOH but also have
prostate cancer which was treated curatively in the past? Only relatively little data are available with small numbers of patients which show that testosterone
substitution therapy is possible without an increased risk of a relapse in cases of cured prostate cancer. If the patient was cured it does not matter if radical
prostatectomy or radiation therapy was used. It is mandatory that patients are well-informed about substitution therapy and that regular surveillance and
controls are carried out during the therapy. For patients who still have prostate cancer which has not yet been treated or not yet cured decisions on whether the
benefit of the testosterone replacement is greater than the potential risk of a progress of the disease have to be made on an individual case-specific basis.
PMID: 21811932 [PubMed - in process]
5. Int Neurourol J. 2011 Jun;15(2):97-101. Epub 2011 Jun 30.
Bicycle riding: impact on lower urinary tract symptoms and erectile function in healthy men.
Baek S, Lee SY, Kim JM, Shin E, Kam S, Jung HC.
Department of Pubic Health, Kyungpook National University School of Medicine, Daegu, Korea.
PURPOSE: Recently, reports in the mass media have implicated that bicycle riding increases the risk of erectile dysfunction and prostatic diseases. So, we
evaluate the impact of bicycle riding on erectile function and lower urinary tract symptoms (LUTS) in healthy general men.
METHODS: From 26 June 2010 to 20 July 2010, we investigate degree of LUTS\ (voiding and storage symptoms), using International Continence Society-male Questionnaire (ICS-mQ) and erectile function using International Index of Erectile Function-5 Questionnaire (IIEF-5) in 5 work places (personnel of public office, hospital, university, etc.) of which bicycle riding club members were doing active club activities. Respondents, who participated in club activities
for 6 months and longer, were classified as the bicycle club (142 men; age, 44.02±8.56). Ones who do not ride bicycles were classified as the control group
(83 men; age, 42.13±7.85). People who were having the history of urological and other chronic diseases (diabetes, vascular disease, heart disease, etc) were
excluded from both groups.
RESULTS: Bicycle club is not significantly associated with increased prevalence of LUTS (bicycle club, 2.1 to 57.7% control, 4.8 to 73.5%) and erectile
dysfunction (bicycle club, 46.1% control, 55.4%). The total mean score (storage/voiding/erectile function) of bicycle club (13.93±1.95/11.14±3.49/20.46±5.30) were not significantly different from control (14.35±2.49/11.52±3.38/20.40±4.07) (P=0.190 to 0.968).
CONCLUSIONS: These results suggested that bicycle riding as exercise or hobby has no negative effect on LUTS and erectile function in healthy general men, although this research data were limited to the questionnaire analysis.
PMID: 21811700 [PubMed - in process]
6. Int Neurourol J. 2011 Jun;15(2):87-91. Epub 2011 Jun 30.
Heart Rate Variability in Men with Erectile dysfunction.
Lee JY, Joo KJ, Kim JT, Cho ST, Cho DS, Won YY, Choi JB.
Department of Urology, Ajou University School of Medicine, Suwon, Korea.
PURPOSE: The objective of this study is to investigate alteration of autonomic nervous system (ANS) activity in patients suffering from erectile dysfunction
(ED) by comparing parameters of heart rate variability (HRV) between men with ED and healthy subjects.
METHODS: A retrospective review was performed on 40 ED patients (mean age, 46.0±8.49 years) without any disease and 180 healthy control people (mean age, 44.4±7.83 years) without ED in our institution from June 2008 to July 2010. And electrocardiographic signals were obtained to measure HRV parameters for both patients and controls in a resting state.
RESULTS: For the time domain analysis, square root of the mean differences between successive RR intervals (RMSSD) representing parasympathetic activity was lower in patients than controls although P-value was not statistically significant (P=0.060). For the frequency domain analysis, high frequency (HF)
representing parasympathetic activity was lower in patients than controls (P=0.232) and low frequency (LF) representing mainly sympathetic activity was
higher in patients than controls (P=0.416). Lastly, LF/HF ratio reflecting sympathetic/parasympathetic activity ratio was statistically higher in patients
than controls (P=0.027).
CONCLUSIONS: Patients with ED exhibited different HRV parameters compared with normal controls. This suggests that the patients with ED may have some kind of imbalance in the ANS and it may be possible that general imbalance of the ANS is one of the causes of ED. Thus, HRV analysis may give valuable diagnostic information and serve as a rapid screening tool to evaluate altered ANS activity in patients with ED.
PMID: 21811698 [PubMed - in process]
7. Nat Rev Urol. 2011 Aug 2. doi: 10.1038/nrurol.2011.112. [Epub ahead of print]
Urological aspects of the metabolic syndrome.
Hammarsten J, Peeker R.
Department of Surgery, Section of Urology, Central Hospital, Rosenborgsgatan 2, S-652 30 Karlstad, Sweden.
The metabolic syndrome is common in countries with Western lifestyles. It comprises a number of disorders-including insulin resistance, hypertension and
obesity-that all act as risk factors for cardiovascular diseases. Urological diseases have also been linked to the metabolic syndrome. Most established
aspects of the metabolic syndrome are linked to benign prostatic hyperplasia (BPH) and prostate cancer. Fasting plasma insulin, in particular, has been linked
to BPH and incident, aggressive and lethal prostate cancer. The metabolic syndrome has also been shown to be associated with nonprostatic urological
conditions such as male hypogonadism, nephrolithiasis, overactive bladder and erectile dysfunction, although data on these conditions are still sparse.
Overall, the results of studies on urological aspects of the metabolic syndrome seem to indicate that BPH and prostate cancer could be regarded as two new
aspects of the metabolic syndrome, and that an increased insulin level is a common underlying aberration that promotes both BPH and clinical prostate cancer.
Urologists need to be aware of the effect that the metabolic syndrome has on urological disorders and should transfer this knowledge to their patients.
PMID: 21811224 [PubMed - as supplied by publisher]
8. J Sex Med. 2011 Aug 2. doi: 10.1111/j.1743-6109.2011.02414.x. [Epub ahead of print]
Effect of Niacin on Erectile Function in Men Suffering Erectile Dysfunction and Dyslipidemia.
Ng CF, Lee CP, Ho AL, Lee VW.
Division of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China.
Introduction. Dyslipidemia is closely related to erectile dysfunction (ED). Evidence has shown that the lipid-lowering agent, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statins), can improve erectile function. However, information about the potential role of another class
of lipid-lowering agent, niacin, is unknown. Aim. To assess the effect of niacin alone on erectile function in patients suffering from both ED and dyslipidemia.
Methods. A single center prospective randomized placebo-controlled parallel-group trial was conducted. One hundred sixty male patients with ED and
dyslipidemia were randomized in a one-to-one ratio to receive up to 1,500 mg oral niacin daily or placebo for 12 weeks. Main Outcome Measures. The primary outcome measure was the improvement in erectile function as assessed by question 3 and question 4 of the International Index of Erectile Function (IIEF Q3 and Q4). Secondary outcome measurements included the total IIEF score, IIEF-erectile function domain, and Sexual Health Inventory for Men (SHIM) score. Results. From the overall analysis, the niacin group showed a significant increase in both IIEF-Q3 scores (0.53 ± 1.18, P < 0.001) and IIEF-Q4 scores (0.35 ± 1.17, P = 0.013) compared with baseline values. The placebo group also showed a significant increase in IIEF-Q3 scores (0.30 ± 1.16, P = 0.040) but not IIEF-Q4 scores (0.24 ± 1.13, P = 0.084). However, when patients were stratified according
to the baseline severity of ED, the patients with moderate and severe ED who received niacin showed a significant improvement in IIEF-Q3 scores (0.56 ± 0.96 [P = 0.037] and 1.03 ± 1.20 [P < 0.001], respectively) and IIEF-Q4 scores (0.56 ± 1.03 [P = 0.048] and 0.84 ± 1.05 [P < 0.001], respectively] compared with baseline values, but not for the placebo group. The improvement in IIEF-EF domain score for severe and moderate ED patients in the niacin group were 5.28 ± 5.94 (P < 0.001) and 3.31 ± 4.54 (P = 0.014) and in the placebo group were 2.65 ± 5.63
(P < 0.041) and 2.74 ± 5.59 (P = 0.027), respectively. There was no significant improvement in erectile function for patients with mild and mild-to-moderate ED for both groups. For patients not receiving statins treatment, there was a significant improvement in IIEF-Q3 scores (0.47 ± 1.16 [P = 0.004]) for the niacin group, but not for the placebo group. Conclusions. Niacin alone can improve the erectile function in patients suffering from moderate to severe ED and dyslipidemia. Ng C-F, Lee C-P, Ho AL, and Lee VWY. Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia. J Sex
PMID: 21810191 [PubMed - as supplied by publisher]
9. J Sex Med. 2011 Aug 2. doi: 10.1111/j.1743-6109.2011.02411.x. [Epub ahead of print]
Sexual Health Outcomes Improvement in Sickle Cell Disease: A Matter of Health Policy?
Burnett AL.
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Introduction. Ischemic priapism is a true male sexual dysfunction, consisting of uncontrollable, prolonged, and often painful erections of the penis. A commonly observed outcome, as a result of erectile tissue damage and fibrosis in this setting, is the complete loss of natural erectile ability. Males with sickle cell
disease (SCD) are commonly affected. Given the adverse health consequences of this condition coupled with its specific population extent, health policy
considerations are warranted. Aim. This article aimed to study circumstances surrounding priapism associated with SCD for the purpose of pushing forward
health policy objectives that improve sexual health-related outcomes. Methods. Medline searches through July 2010 were conducted using the following terms: priapism, sickle cell disease, epidemiology, public health, health economics, and health policy. Main Outcome Measure. Expert opinion was based on review of the medical literature related to this subject matter. Results. The literature search affirmed that SCD-associated priapism threatens sexual health and also exerts a greatly negative impact on the physical and mental health of affected individuals. Various socioeconomic, behavioral, and cultural factors in the SCD population bearing negatively on sexual health outcomes were delineated. Deficiencies in several aspects of medical services for patients with SCD
including scientific research funding support, which evoke an element of ethnic healthcare disparities, were further delineated. Conclusions. SCD-associated
priapism is a medical condition of societal health significance, which can and should be addressed through comprehensive healthcare programmatic efforts. These efforts comprise advancement of educational and clinical training programs, support of interdisciplinary healthcare delivery services, diffusion of clinical
advances, enactment of guidelines for effective clinical management, and resource allocation for enabling scientific advancements. Burnett AL. Sexual health
outcomes improvement in sickle cell disease: A matter of health policy? J Sex Med
PMID: 21810190 [PubMed - as supplied by publisher]
10. J Sex Med. 2011 Aug 2. doi: 10.1111/j.1743-6109.2011.02407.x. [Epub ahead of print]
Association Between Urinary Calculi and Erectile Dysfunction: A Case-Control Study.
Chung SD, Keller JJ, Lin HC.
Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Ban Ciao, Taipei, Taiwan Graduate Institute of Clinical Medicine, College of
Medicine, National Taiwan University, Taipei, Taiwan School of Health Care Administration, Taipei Medical University, Taipei, Taiwan School of Medical
Laboratory Sciences and Biotechnology, Taipei Medical University, Taipei, Taiwan.
Introduction. Stone disease is associated with systemic metabolic and hormonal disorders that share common risk factors with erectile dysfunction (ED); however, few studies have investigated the association between ED and urinary calculi (UC). Aim. This case-control study aims to estimate the association of ED with UC using a nationwide, population-based database in Taiwan. Methods. We identified 5,620 patients with ED as the study group and randomly selected 16,860 patients as the controls. We estimated the odds ratio (OR) and 95% confidence interval (CI) of having previously been diagnosed with UC according to the presence/absence of ED using conditional logistic regression after adjusting for hypertension, diabetes, coronary heart disease, and hyperlipidemia. Main Outcome Measure. We measured the prevalence and risk of UC between the cases and controls. We only included UC cases if the UC diagnosis was made previous to the index date. Results. Of the sampled patients, 3,855 (17.2%) were found to have been diagnosed with UC prior to the index date; 1,251 (22.3%) ED patients and 2,604 (15.4%) controls had been diagnosed with UC, respectively. After adjusting for confounders, the OR in ED patients who had prior UC was 1.46 (95% CI = 1.35-1.58) when compared with controls. The ORs of UC for ED patients were somewhat higher in younger groups. In particular, when compared with controls the adjusted OR in ED patients between 40 and 49 years old for prior UC was 1.73 (95%
CI = 1.48-2.02). Conclusions. ED is associated with cases having a prior diagnosis of UC, particularly in younger populations. Chung S-D, Keller JJ, and
Lin H-C. Association between urinary calculi and erectile dysfunction: Acase-control study. J Sex Med
PMID: 21810186 [PubMed - as supplied by publisher]
11. Clinics (Sao Paulo). 2011;66(6):1119-21.
A young man with position-dependent erectile dysfunction: diagnostic work-up and interventional therapy of an arteriovenous malformation.
Huber J, Schild HH, Huber CG, Hallscheidt P, Hohenfellner M.
Department of Urology, University of Heidelberg, Germany.
PMCID: PMC3129943 PMID: 21808888 [PubMed - in process]
12. Int Angiol. 2011 Oct;30(5):415-23.
New immunophenotype of circulating endothelial progenitor cells and endothelial microparticles in patients with erectile dysfunction and metabolic syndrome:
effects of tadalafil administration.
La Vignera S.
Section of Endocrinology, Andrology and Internal Medicine, Human Reproduction and Biotechnology Sciences, Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy - sandrolavignera@email.it.
AIM: Circulating endothelial progenitor cells (EPCs) and endothelial microparticles (EMPs) increase, respectively, in the attempt to repair the
damaged endothelium and in response to endothelial dysfunction. Erectile dysfunction (ED) of arterial origin recognizes endothelial dysfunction as one of
its main determinants and shares risk factors and physiopathological evolution with the metabolic syndrome (MetS). Tadalafil, selective inhibitor of
phosphodiesterase V, long half-life, is used to treat erectile dysfunction, and several studies have already documented the beneficial effects on endothelial
dysfunction. The aim of this paper was to evaluate the concentrations of EPCs and EMPs in patients with arterial ED and MetS, before and after tadalafil
administration, and in healthy men. METHODS: Thirty patients (47-54 years) with ED and MetS (ATP III 1999 criteria) and 17 healthy men (44-57 years) were selected. EPCs (CD45neg/CD34pos/CD144pos) and EMPs (CD45neg/CD34neg/CD144pos) blood concentrations were evaluated by flow
cytometry before and after administration of tadalafil (20 mg) on demand for 3 months. After treatment, the patients were divided into responders and poor
responders, according to their IIEF-5 score. Main outcome measures: Blood EPCs and EMPs.
RESULTS: Before treatment, the percentage of EPCs and EMPs was significantly higher in patients with ED and MetS compared to healthy men. Treatment with tadalafil increased significantly EPCs in both responders and poor responders. The latter had significantly higher EPCs compared to responders, both before and after tadalafil. Before tadalafil, EMPs were higher, but not significantly, in poor responders vs. responders. No significant change occurred after tadalafil administration in both responders and poor responders. A significant positive correlation was found between EPCs and age, Body Mass Index (BMI), acceleration time, IMT and EDV; whereas a negative correlation was found with IIEF-5 score, PSV and resistance index. EMPs correlated positively with BMI, acceleration time and IMT and negatively with the IIEF-5 score.
CONCLUSION: Tadalafil increased the percentage of EPCs in both responders and poor responders, suggesting the persistence of an adequate bone marrow response. The unchanged EMP concentrations after tadalafil suggest a reduction of the dysfunctional mechanism.
PMID: 21804479 [PubMed - in process]
13. Int Angiol. 2011 Oct;30(5):408-14.
Increased expression of endothelial-platelet dysfunctional pathway in patients with arterial erectile dysfunction.
La Vignera S.
Section of Endocrinology, Andrology and Internal Medicine, Human Reproduction and Biotechnological Sciences, Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy - sandrolavignera@email.it.
AIM: Pathophysiological externalization of specific substances belonging to the vessel wall (after endothelial injury), usually not in contact with the blood
(subintimal area) is the signal which is captured by surface receptor platelet's results in their adhesion. There are no studies that have so far examined the
expression of these receptors in patients with arterial erectile dysfunction (ED). The aim of this study was to assess by flow cytometry, serum concentration
of apoptotic endothelial microparticles (EMPa) and vitronectin receptor (VR) in aselected series of patients with arterial ED and without apparent other sistemic
arterial involvement.
METHODS: Evaluated consecutively 50 selected patients with arterial ED-based (mean IIEF-5 score of 6.3±0.3 and mean peak systolic velocity of 24.5±0.6 cm/s). Evaluation of EMPa and VR was conducted using a flow cytometer. The events CD45neg-CD144pos-annexinVpos were defined EMPa, while events
CD51pos-CD61pos-CD41neg were defined VR.
RESULTS: Patients with arterial ED had a serum baseline concentrations of circulating EMPa (12.2±2.2% vs. 1.8±0.4%) and VR (7.4±1.2% vs. 1.2±0.2%)
significantly higher than control group.
CONCLUSION: The present study shows that patients with arterial ED had an increased expression of endothelial apoptosis and initial platelet adhesion.
PMID: 21804478 [PubMed - in process]
14. Med Hypotheses. 2011 Jul 29. [Epub ahead of print]
Does l-arginine supplementation play a role in cerebral small vessels disease? Implication in the treatment of leukoaraiosis.
Calabrò RS, Gervasi G, Bramanti P.
IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Although leukoaraiosis can be considered as a part of the normal aging process, it is strongly associated with stroke, cognitive impairment and other
disabilities. The pathogenesis of leukoaraiosis is poorly understood, even if chronic ischemia with consequent arteriolosclerosis probably due to endothelial
dysfunction has been suggested. To date, treatment focuses only on prevention of lesion formation and progression by aggressive control of risk factors, beginning at an early age and continuing throughout life. l-Arginine, a semi-essential amino acid, is a precursor of NO in the reaction catalyzed by endothelial nitric oxide synthase and, it has been recently found to importantly influence endothelial function. Arginine supplementation has been demonstrated to be safe
and effective therapy for many health conditions, particularly vascular diseases such as intermittent claudication, angina pectoris, erectile dysfunction and
MELAS. Thus we hypothesize that, since a lack of endothelium-derived NO may be responsible for several features of LA, long-term administration of high oral doses of l-Arg may slow LA progression and the associated functional impairment.
PMID: 21803504 [PubMed - as supplied by publisher]
15. Med Hypotheses. 2011 Jul 28. [Epub ahead of print]
Propofol's derivative: A potential drug for erectile dysfunction?
Sweni S, Meenakshisundaram R, Senthilkumaran S, Thirumalaikolundusubramanian P.
Department of General Medicine, Chennai Medical College Hospital and Research
Centre, Irungalur, Trichy, India.
Propofol, an intravenous anesthetic agent induces priapism in humans. We hypothesize the probable central nervous system and local mechanisms through
which a similar molecule can be used as a therapy in erectile dysfunction. Previous literatures published over a period of 35years (1976-2010) were searched
using the key words, mechanisms were identified and discussed. In the central nervous system, propofol has an inhibitory effect on serotonin receptors and on
gamma-aminobutyric acid A (GABA-A) receptors as well as a facilitatory action on N-methyl-d-aspartate (NMDA) mediated calcium response and agonistic action on dopaminergic D2 receptors, which might contribute towards maintaining erections. While in the penile tissue, propofol's action may be due to increased synthesis of nitric oxide (NO), the principal mediator of penile erection. In addition, it may also have inhibitory effect on thromboxane A2, a potent vasoconstrictor and stimulatory action on penile adenosine triphosphate (ATP) dependent potassium (K-ATP) channels, a potent vasodilator. In view of the above mechanisms, use ofpropofol or similar molecule in erectile dysfunction needs to be ascertained and evaluated.
PMID: 21802862 [PubMed - as supplied by publisher]
16. J Ethnopharmacol. 2011 Jul 20. [Epub ahead of print]
Preclinical evaluation of Trichilia catigua extracts on the central nervous system of mice.
Chassot JM, Longhini R, Gazarini L, Mello JC, de Oliveira RM.
Laboratory of Neuropsychopharmacology, Department of Pharmacy and Pharmacology, State University of Maringá, Av. Colombo n. 5790, 87020-900 Maringá, Paraná, Brazil.
ETHNOPHARMACOLOGICAL RELEVANCE: Trichilia catigua preparations have been popularly used in Brazil as a tonic for the treatment of fatigue, stress, impotence, and deficiency of memory. The aim of the present study was to investigate the possible antidepressant, anxiolytic, motor and cognitive effects of the crude extract (CE) or ethyl-acetate fraction (EAF) of Trichilia catigua. Analyses of the total phenolics and total tannins content, as well as the in
vitro antioxidant activity of CE and EAF were also performed. MATERIALS AND METHODS: CE (200-800mg/kg) and EAF (100-400mg/kg) were orally administered to mice and 1h later the behavioral tests were performed. The free radical scavenging activity was measured by using 2,2-diphenyl-1-picryl-hydrazyl (DPPH) method. RESULTS: Single administration of CE (200-400mg/kg) or EAF (100-400mg/kg) did not change the behavior of the animals submitted to the elevated plus maze ortheir locomotor activity in the open field test. An antidepressant-like effect was detected with EAF (400mg/kg) after acute administration. Both CE (800mg/kg) and EAF (200 and 400mg/kg), improve memory in mice as measured by an increased
latency in the step-down inhibitory avoidance test. The EAF presented higher total phenolics and total tannins as compared to CE as well as it exhibited the
best antioxidant activity. CONCLUSIONS: The present results showed an in vitro antioxidant activity for EAF and suggested that it may be useful for cognitive
improvement. It is possible that both functional and chemical activities are related.
PMID: 21801825 [PubMed - as supplied by publisher]
17. Int J Clin Pract. 2011 Aug 1. doi: 10.1111/j.1742-1241.2011.02729.x. [Epub ahead of print]
An e-mail and telephone helpline for sexual problems - results of a 2-year survey of men's sexual concerns.
Tomlinson JM, Fernandes LC, Wylie KR.
Men's Health Clinic, Royal Hampshire County Hospital, Winchester, UK School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
Sheffield Care NHS Trust, Psychosexual Medicine, Sheffield, UK.
Introduction: Sexual problems are relatively common in the community. The under-reporting of such problems calls for alternative ways of getting a true
perspective of the prevalence of sexual dysfunction. Aim: To assess and investigate the concerns, ages and nationality of male users of a electronic
helpline using it over 2 years (2009-2010). Methods: Detailed records were kept of all emails and telephone calls to the helpline which included administrative
and clinical queries. The clinical calls and some of the emails were answered by the administrator, while the majority of the emails were answered by a physician. This presentation will deal with the users who emailed for assistance with male sexual dysfunction. (n = 673). Results: The helpline received a total of 6142 calls over the period of investigation, including administrative and press calls. Men accounted for 88% of the callers about sexual dysfunction. Erectile
dysfunction accounted for 68% of the complaints by men who used the e-mail service. Premature ejaculation, loss of sex drive, genital problems and
masturbation worries were other concerns that were received. A large number of men from the Middle East and the Indian sub-continent used the email service,
mostly for premature ejaculation and masturbation worries, related to their arranged marriage. Conclusions: We found confirmation that the commonest sexual
complaints in men were of erectile dysfunction and loss of sex drive. Significant correlations were identified between the types of sexual dysfunction and the age
and ethnicity of the men who presented with them.
PMID: 21801284 [PubMed - as supplied by publisher]
18. J Androl. 2011 Jul 28. [Epub ahead of print]
Castration for Treating Recurrent Priapism: Can We Do Better?
Burnett AL.
Letter to the Editor: Our case report describing the management of recurrent priapism in a man using continuous, non-stimulatory phosphodiesterase type-5
inhibitor therapy after restored eugonadal status (Pierorazio et al, 2011) has caused me to further reflect on the profound adversity of long-term androgen
ablation as a prescription for this condition. As for other patients treated for priapism in my clinical experience, our patient endured considerable side effects
of his testosterone deficiency for many years, including loss of vitality, decreased libido and erectile dysfunction as well as gynecomastia. Such effects,
which may additionally encompass increased abdominal body fat and reduced muscle mass and strength symptomatically as well as clinical complications of
cardiovascular disease, dementia, metabolic syndrome with glucose intolerance, and osteoporosis, are well recognized and increasingly voiced major ill health
concerns of the aging male and of patients with prostate cancer receiving androgen ablative therapies. Should these concerns be any less considerable for
patients with priapism?
PMID: 21799141 [PubMed - as supplied by publisher]
19. Urol Clin North Am. 2011 Aug;38(3):293-301. Epub 2011 Jun 12.
Lifestyle/Dietary recommendations for erectile dysfunction and female sexual dysfunction.
Esposito K, Giugliano D.
Department of Cardio-Thoracic and Respiratory Sciences, Second University of Naples, Piazza L. Miraglia 2, 80138 Naples, Italy.
Sexual problems are diffuse in both genders. Although epidemiologic evidence seems to support a role for lifestyle factors in erectile dysfunction, limited
data are available suggesting the treatment of underlying risk factors may improve erectile dysfunction. The results are sparse regarding associations
between lifestyle factors and female sexual dysfunction, and conclusions regarding influence of healthy behaviors on female sexual dysfunction cannot be
made before more studies have been performed. Beyond the specific effects on sexual dysfunctions in men and women, adoption of these measures promotes a
healthier life and increased well-being, which may help reduce the burden of sexual dysfunction.
PMID: 21798391 [PubMed - in process]
20. J Sex Med. 2011 Jul 28. doi: 10.1111/j.1743-6109.2011.02391.x. [Epub ahead ofprint]
A Randomized Controlled Trial of Guided Internet-delivered Cognitive Behavioral Therapy for Erectile Dysfunction.
Andersson E, Walén C, Hallberg J, Paxling B, Dahlin M, Almlöv J, Källström R, Wijma K, Carlbring P, Andersson G.
Department of Behavioural Sciences and Learning, Linköping University, Sweden Swedish Institute for Disability Research, Linköping University, Sweden
Department of Clinical Neuroscience, Division of Psychiatry, Karolinska Institutet, Stockholm, Sweden Psykologpartners, Linköping, Sweden Department of
Urology, University Hospital Linköping, Linköping, Sweden Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden Department of Psychology, Umeå University, Umeå, Sweden.
Introduction. Men with erectile dysfunction are often worried about their condition, have interpersonal difficulties, and have a reduced quality of life.
Internet-delivered cognitive behavior therapy (ICBT) has been shown effective for a number of health problems but evidence is limited concerning the treatment of erectile dysfunction. Aim. The study investigated the effects of ICBT for erectile dysfunction. Methods. Seventy-eight men were included in the study and
randomized to either ICBT or to a control group, which was an online discussion group. Treatment consisted of a 7-week Web-based program with e-mail-based therapist support. Each therapist spent an average of 55 minutes per participant. Main Outcome Measure. The International Index of Erectile Functioning five-item version was administered via the telephone at pretreatment, post-treatment, and 6 months after receiving ICBT. Results. At post-treatment, the treatment group had significantly greater improvements with regard to erectile performance compared with the control group. Between-group differences at post-treatment were small (d = 0.1), but increased at the 6-month follow-up (d = 0.88). Conclusions. This
study provides support for the use of ICBT as a possible treatment format forerectile dysfunction. Andersson E, Walén C, Hallberg J, Paxling B, Dahlin M,
Almlöv J, Källström R, Wijma K, Carlbring P, and Andersson G. A randomized controlled trial of guided Internet-delivered cognitive behavioral therapy for
erectile dysfunction. J Sex Med **;**:**-**.
PMID: 21797983 [PubMed - as supplied by publisher]
PMID: 17317653 [PubMed - indexed for MEDLINE]
Sources :- http://www.pubmedcentral.nih.gov